Oxford coronavirus vaccine: Why have trials paused?
Human trials have paused for the coronavirus vaccine, but is this a setback for vaccine research?
Human trials of the coronavirus vaccine being developed by the University of Oxford and AstraZeneca have been put on hold owing to a reported side effect in a patient in the UK.
AstraZeneca said it was investigating whether the patient’s reported side effect is connected with the vaccine.
But is this a setback for the development of the vaccine, and what happens next?
What is the Oxford vaccine?
The coronavirus vaccine, called ChAdOx1 nCoV-19, uses a weakened version of a common cold virus (adenovirus) which causes infections in chimpanzees.
It has been genetically changed so it is impossible for it to grow in humans.
It is hoped the vaccine will make the body recognise and develop an immune response to the spike protein – recognisable in images of the virus – that will help stop COVID-19 from entering human cells and therefore prevent infection.
Read more about the Oxford vaccine:
- Oxford vaccine could be put before regulators by the end of the year
- Oxford vaccine shows 'strong antibody and T-cell immune response'
- Manufacturing begins on 'millions of doses' of the Oxford vaccine candidate
Why have trials been put on hold?
AstraZeneca issued a statement saying the late-stage studies of the vaccine had been paused while the company investigates whether the patient’s reported side effect was connected with the vaccine.
A spokeswoman said the pause was part of a standard review process which occurs in trials if there is a “potentially unexplained illness” reported in any trial subject, and that the subject’s illness could also be coincidental.
No details about the patient suffering the potential side effect, or the nature of the reaction, were given.
But The New York Times has reported that the patient had been diagnosed with transverse myelitis, an inflammatory syndrome that affects the spinal cord often sparked by viral infections.
What happens next?
AstraZeneca said it had voluntarily paused vaccination to allow review of safety data by an independent committee to take place.
Wellcome Trust director and Sage member Professor Sir Jeremy Farrar told BBC Radio 4’s Today programme that such an occurrence is quite common but each one must be taken seriously.
He said an independent investigation would look at whether the illness in the trial volunteer is related to the vaccine or placebo and, if not, then the trial can restart safely.
Prof Farrar added that it is inevitable that some of the 30,000 to 40,000 people given the vaccine will have illnesses unrelated to it.
Is this a setback?
Temporary holds of large medical studies are not uncommon, and looking into any unexpected reactions is a mandatory part of safety testing.
It was not immediately clear how long AstraZeneca’s pause would last.
Health Secretary Matt Hancock said the Oxford vaccine trial had been paused earlier in the year.
He said: “There was a pause earlier in the summer and that was resolved without a problem.”
How are the trials progressing?
The vaccine is being trialled in tens of thousands of volunteers in the UK, South Africa, Brazil and the US.
It is expected that there will be up to 50,000 participants globally, the University of Oxford has said.
This trial aims to assess how well people across a broad range of ages could be protected from COVID-19.
Results from the late-stage trials are anticipated later this year, the university has said.
Read more about coronavirus vaccines:
- Who should get a vaccine first?
- Cambridge vaccine gets £1.9 million to begin clinical trials
- American vaccine produces 'robust immune response' in human trials
What did the preliminary results suggest?
The results of the clinical trials, published in The Lancet in July, indicate that the vaccine candidate has triggered two responses in the immune system.
The first is that it stimulates the immune system to produce antibodies – proteins produced by the blood in response to antigens which are harmful substances that come from outside the body, such as from viruses or bacteria – and that it also causes the body to produce T-cells.
If the non-specific immune cells which respond to any invader instantly cannot tackle it, the T-cells come into play.
These cells attack the virus directly.
With questions remaining about the duration of the antibody response to COVID-19, research suggests T-cells have a more important role in offering protection against the disease.
How do scientists develop vaccines for new viruses?Vaccines work by fooling our bodies into thinking that we’ve been infected by a virus. Our body mounts an immune response, and builds a memory of that virus which will enable us to fight it in the future.
Viruses and the immune system interact in complex ways, so there are many different approaches to developing an effective vaccine. The two most common types are inactivated vaccines (which use harmless viruses that have been ‘killed’, but which still activate the immune system), and attenuated vaccines (which use live viruses that have been modified so that they trigger an immune response without causing us harm).
A more recent development is recombinant vaccines, which involve genetically engineering a less harmful virus so that it includes a small part of the target virus. Our body launches an immune response to the carrier virus, but also to the target virus.
Over the past few years, this approach has been used to develop a vaccine (called rVSV-ZEBOV) against the Ebola virus. It consists of a vesicular stomatitis animal virus (which causes flu-like symptoms in humans), engineered to have an outer protein of the Zaire strain of Ebola.
Vaccines go through a huge amount of testing to check that they are safe and effective, whether there are any side effects, and what dosage levels are suitable. It usually takes years before a vaccine is commercially available.
Sometimes this is too long, and the new Ebola vaccine is being administered under ‘compassionate use’ terms: it has yet to complete all its formal testing and paperwork, but has been shown to be safe and effective. Something similar may be possible if one of the many groups around the world working on a vaccine for the new strain of coronavirus (SARS-CoV-2) is successful.